Boditech Med KRX:206640KOSDAQ
바디텍메드 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Boditech Med reported revenue of ₩48.0bn, up 20.1% year on year, and operating profit of ₩8.9bn. Boditech Med (바디텍메드) appeared in 0 Korean news articles and 5 DART filings over the past seven days. Coverage peaked on Nov 6 with 8 articles. The most common catalyst was earnings (6). It was most often mentioned alongside Seers.
Filing signals Revenue & profit growth Insider buying Major holder adding Insider selling Screener
Boditech Med at a glance from DART filings
- Results trend
- Operating profit in each of the last 4 quarters; Q3 2026 operating profit of ₩8.9bn rose from the previous quarter.
- Ownership changes
- 4 5%-holder and insider ownership reports in the past 120 days (3 increases, 1 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Boditech Med today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Boditech Med stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Boditech Med quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩48.0bn | +20.1% | ₩8.9bn margin 18.6% | ₩2.0bn |
| Q2 2026 | ₩50.4bn | +21.5% | ₩8.2bn margin 16.3% | ₩7.6bn |
| Q1 2026 | ₩42.8bn | +9.6% | ₩6.8bn margin 15.9% | ₩9.5bn |
| Q4 2025 derived | ₩41.6bn | +33.1% | ₩5.1bn margin 12.2% | ₩1.4bn |
| Q3 2025 | ₩39.9bn | +6.3% | ₩6.6bn margin 16.5% | ₩7.8bn |
| Q2 2025 | ₩41.5bn | +14.4% | ₩9.2bn margin 22.2% | ₩7.5bn |
| Q1 2025 | ₩39.1bn | +18.1% | ₩8.1bn margin 20.7% | ₩7.3bn |
| Q4 2024 derived | ₩31.2bn | -10.6% | ₩2.2bn margin 6.9% | ₩4.8bn |
Boditech Med ranks #444 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Boditech Med top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Boditech Med news Korean headlines
-
Bodytech Med's Q3 operating profit rises 35%, driven by strong cartridge sales
2 more on this story · 2 outlets
-
BodyTech Med shares diabetes diagnosis and TDM clinical cases at LMCE 2026
3 more on this story · 3 outlets
- Bodytech Med shares diabetes precision medicine and rapid TDM clinical cases at LMCE라포르시안 · Oct 26 14:50
- Bodytech Med shares diabetes and TDM clinical cases at LMCE글로벌경제신문 · Oct 26 14:57
- Bodytech Med in Chuncheon shares diabetes precision medicine and rapid TDM clinical cases at LMCE 2026강원도민일보 · Oct 26 15:34